Remdesivir, hailed as potential COVID-19 treatment, gets emergency U.S. FDA green light

Must Read

City of Fort St John working on plans to reopen facilities

FORT ST. JOHN, B.C. - As the Province begins to reopen, following the suspension of services due to the...

Active COVID-19 cases continues to drop in BC, 2,207 have now recovered

VICTORIA, B.C. – The total number of confirmed COVID-19 cases in the Northern Health Region is still at 64...

Temporary use permits discussed at PRRD meeting

The Peace River Regional District went over the finer points of temporary use permits on May 28,...

Remdesivir has received emergency use authorization (EUA) from the U.S. Food and Drug Administration after a major study showed that it can reduce recovery time for hospitalized COVID-19 patients.

In a news release on Friday, the FDA said it has issued the EUA for “treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.”

Gilead’s investigational antiviral for the treatment of COVID-19 receives @US_FDA Emergency Use Authorization. This more readily enables treatment of hospitalized patients with severe COVID-19 disease in the United States. Read more: https://t.co/p4LR0RM7sI. pic.twitter.com/4kg9oDQPRq

- Advertisement -

Community Interviews with Moose FM


— Gilead Sciences (@GileadSciences) May 1, 2020

Story continues below advertisement

The FDA acknowledged there is “limited information” so far about how effective or safe the drug is.

Preliminary results from a 1,063-patient clinical trial by the U.S. National Institutes of Health showed that patients given remdesivir recovered in a shorter than those given a placebo.

1:39Remdesivir: Drug shows promise as COVID-19 treatment

Remdesivir: Drug shows promise as COVID-19 treatment

U.S.

Advertisement


 » READ MORE FROM GLOBAL NEWS

More Articles Like This